Exploration of Medicine

Table 1. Studies of the composition of granulomas and interstitial lung tissue in the BCG-induced granulomatous model

Parameter	Reference
Parameter	[15]	[16]	[36]	[73]	[77]	[95]
Time after BCG infection (days)	3, 30	14–28	3–180	3–180	30–180	7–28
Lung granulomas
Numerical density	√		√		√
Diameter	√		√		√
Сollagen fibers	√		√		√
TNF-α			√		√
Caspase 3					√
TRAIL					√
Macrophages		√	√		√
Fibroblasts	√		√		√
Epithelioid cell		√			√
Lymphocyte		√			√
Lung interstitium
Collagen fibers	√		√		√
sGAG				√
Protein				√
Uronic acids				√
Galactose				√
Hydroxyproline	√		√			√
TNF-α			√
TGF-β						√
Macrophages			√
Fibroblasts			√

Return to article view

Blank cells represent no description. TRAIL: TNF-related apoptosis-inducing ligand; sGAG: sulfated GAG; TGF-β: transforming growth factor-β; √: included in the study

Declarations

Author contributions

LBK: Conceptualization, Methodology, Investigation, Writing—original draft, Writing—review & editing. ANP: Data curation, Formal analysis, Investigation, Project administration, Validation. Both authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by budgetary funding for basic scientific research of Fundamental and Translational Medicine, Russia. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

World Health Organization. Global tuberculosis report 2022. Geneva: The Organization; 2022.

Ministry of Health of the Republic of Indonesia, Directorate General of Disease Prevention and Environmental Health. Pedoman Nasional Pengendalian Tuberkulosis: Indonesia Bebas Tuberkulosis. Jakarta: The Directorate; 2014. Indonesian.

Christine T, Tarigan AP, Ananda FR. The correlation between levels of transforming growth factor-β with pulmonary fibrosis in post pulmonary tuberculosis in Medan, North Sumatera – Indonesia. Open Access Maced J Med Sci. 2019;7:2075–8. [DOI] [PubMed] [PMC]

Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci. 2004;9:283–9. [DOI] [PubMed]

Strieter RM. What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis. Proc Am Thorac Soc. 2008;5:305–10. [DOI] [PubMed] [PMC]

DiFazio RM, Mattila JT, Klein EC, Cirrincione LR, Howard M, Wong EA, et al. Active transforming growth factor-β is associated with phenotypic changes in granulomas after drug treatment in pulmonary tuberculosis. Fibrogenesis Tissue Repair. 2016;9:6. [DOI] [PubMed] [PMC]

Evans S, Butler JR, Mattila JT, Kirschner DE. Systems biology predicts that fibrosis in tuberculous granulomas may arise through macrophage-to-myofibroblast transformation. PLoS Comput Biol. 2020;16:e1008520. [DOI] [PubMed] [PMC]

Harada S, Harada Y, Kitara Y, Takamoto M, Ishibashi T, Sininoda A. Tuberculosis sequelae: clinical aspects. Kekkaku. 1990;65:831–8. Japanese. [PubMed]

Kim HY, Song KS, Goo JM, Lee JS, Lee KS, Lim TH. Thoracic sequelae and complication of tuberculosis. Radiographics. 2001;21:839–58. [DOI] [PubMed]

10.

Menon B, Nima G, Dogra V, Jha S. Evaluation of the radiological sequelae after treatment completion in new cases of pulmonary, pleural, and mediastinal tuberculosis. Lung India. 2015;32:241–5. [DOI] [PubMed] [PMC]

11.

Deshpande SS, Joshi AR, Shah A. Aftermath of pulmonary tuberculosis: computed tomography assessment. Pol J Radiol. 2020;85:e144–54. [DOI] [PubMed] [PMC]

12.

Kuwano K, Hagimata N, Hara N. Pulmonary fibrogenesis. In: Fibrogenesis: cellular and molecular basis. Boston (MA): Springer; 2005. pp. 178–98.

13.

Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair. 2012;5:11. [DOI] [PubMed] [PMC]

14.

Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev. 2018;27:170077. [DOI] [PubMed] [PMC]

15.

Shkurupiy VA, Kim LB, Nikonova IK, Potapova OV, Cherdantseva LA, Sharkova TV. Hydroxyproline content and fibrogenesis in mouse liver and lungs during the early stages of BCG granulomatosis. Bull Exp Biol Med. 2013;154:299–302. [DOI] [PubMed]

16.

Polyakov LM, Knyasev RA, Kotova MV, Russkikh GS, Soloveva EI, Ryabchenko AV. Apolipoprotein A-I increases the activity of lysosomal glycosidases in the liver of mice with BCG-induced tuberculosis inflammation. Sib Sci Med J. 2021;41:51–5. Russian. [DOI]

17.

Jacobs M, Samarina A, Grivennikov S, Botha T, Allie N, Fremond C, et al. Reactivation of tuberculosis by tumor necrosis factor neutralization. Eur Cytokine Netw. 2007;18:5–13. [DOI] [PubMed]

18.

Kondratieva TK, Linge IA, Kondratieva EV, Dyatlov AV, Drutskaya MS, Zvartsev RV, et al. Formation of compact aggregates of B-lymphocytes in lung tissue during mycobacterial infection in mice depends on TNF production by these cells and is not an element of the host’s immunological protection. Biochemistry (Mosc). 2014;79:1358–62. [DOI] [PubMed]

19.

Jacobs M, Brown N, Allie N, Ryffel B. Fatal Mycobacterium bovis BCG infection in TNF-LT-α-deficient mice. Clin Immunol. 2000;94:192–9. [DOI] [PubMed]

20.

Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Shakhov AN, et al. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity. 2005;22:93–104. [DOI] [PubMed]

21.

Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol. 2003;171:3110–8. [DOI] [PubMed]

22.

Feldmann M, Brennan FM, Elliott MJ, Williams RO, Maini RN. TNFα is an effective therapeutic target for rheumatoid arthritis. Ann N Y Acad Sci. 1995;766:272–8. [DOI] [PubMed]

23.

Quesniaux VF, Jacobs M, Allie N, Grivennikov S, Nedospasov SA, Garcia I, et al. TNF in host resistance to tuberculosis infection. Curr Dir Autoimmun. 2010;11:157–79. [DOI] [PubMed]

24.

Warsinske HC, DiFazio RM, Linderman JJ, Flynn JL, Kirschner DE. Identifying mechanisms driving formation of granuloma-associated fibrosis during Mycobacterium tuberculosis infection. J Theor Biol. 2017;429:1–17. [DOI] [PubMed] [PMC]

25.

Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, Koch C, et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol. 2006;8:218–32. [DOI] [PubMed]

26.

Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol. 2005;33:9–13. [DOI] [PubMed]

27.

Kramnik I, Beamer G. Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies. Semin Immunopathol. 2016;38:221–37. [DOI] [PubMed] [PMC]

28.

Young D. Animal models of tuberculosis. Eur J Immunol. 2009;39:2011–4. [DOI] [PubMed]

29.

Soldevilla P, Vilaplana C, Cardona PJ. Mouse models for Mycobacterium tuberculosis pathogenesis: show and do not tell. Pathogens. 2023;12:49. [DOI] [PubMed] [PMC]

30.

Dale PD, Sherratt JA, Maini PK. Role of fibroblast migration in collagen fiber formation during fetal and adult dermal wound healing. Bull Math Biol. 1997;59:1077–100. [DOI] [PubMed]

31.

Witte MB, Barbul A. General principles of wound healing. Surg Clin North Am. 1997;77:509–28. [DOI] [PubMed]

32.

Robson MC, Steed DL, Franz MG. Wound healing: biologic features and approaches to maximize healing trajectories. Curr Probl Surg. 2001;38:72–140. [DOI] [PubMed]

33.

Velnar T, Bailey T, Smrkolj V. The wound healing process: an overview of the cellular and molecular mechanisms. J Int Med Res. 2009;37:1528–42. [DOI] [PubMed]

34.

Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol. 2010;298:L715–31. [DOI] [PubMed] [PMC]

35.

Randall PJ, Hsu NJ, Quesniaux V, Ryffel B, Jacobs M. Mycobacterium tuberculosis infection of the ‘non-classical immune cell’. Immunol Cell Biol. 2015;93:789–95. [DOI] [PubMed]

36.

Shkurupiy VA, Kim LB, Potapova OV, Cherdantseva LA, Putyatina AN, Nikonova IK. Fibrogenesis in granulomas and lung interstitium in tuberculous inflammation in mice. Bull Exp Biol Med. 2014;156:731–5. [DOI] [PubMed]

37.

Allie N, Grivennikov SI, Keeton R, Hsu NJ, Bourigault ML, Court N, et al. Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection. Sci Rep. 2013;3:1809. [DOI] [PubMed] [PMC]

38.

Harding JS, Rayasam A, Schreiber HA, Fabry Z, Sandor M. Mycobacterium-infected dendritic cells disseminate granulomatous inflammation. Sci Rep. 2015;5:15248. [DOI] [PubMed] [PMC]

39.

Sorushanova A, Delgado LM, Wu Z, Shologu N, Kshirsagar A, Raghunath R, et al. The collagen suprafamily: from biosynthesis to advanced biomaterial development. Adv Mater. 2019;31:e1801651. [DOI] [PubMed]

40.

Omel’yanchenko NP, Slutskii LI. Connective tissue: histophysiology and biochemistry. Mironov SP, editor. Moscow: Izvestiya; 2009. Russian.

41.

Gordon MK, Hahn RA. Collagens. Cell Tissue Res. 2010;339:247–57. [DOI] [PubMed] [PMC]

42.

Liu L, Stephens B, Bergman M, May A, Chiang T. Role of collagen in airway mechanics. Bioengineering (Basel). 2021;8:13. [DOI] [PubMed] [PMC]

43.

Suki B, Ito S, Stamenovic D, Lutchen KR, Ingenito EP. Biomechanics of the lung parenchyma: critical roles of collagen and mechanical forces. J Appl Physiol. 2005;98:1892–9. [DOI] [PubMed]

44.

Suki B, Bates JH. Extracellular matrix mechanics in lung parenchymal diseases. Respir Physiol Neurobiol. 2008;163:33–43. [DOI] [PubMed] [PMC]

45.

Faffe DS, Zin WA. Lung parenchymal mechanics in health and disease. Physiol Rev. 2009;89:759–75. [DOI] [PubMed] [PMC]

46.

Faffe DS, Silva GH, Kurtz PM, Negri EM, Capelozzi VL, Rocco PR, et al. Lung tissue mechanics and extracellular matrix composition in a murine model of silicosis. J Appl Physiol. 2001;90:1400–6. [DOI] [PubMed]

47.

Esmedlyaeva DS, Alekseeva NP, Kiryukhina LD, Dyakova ME. Matrix metalloproteinases in pathogenesis of ventilation disorders of the respiratory system in patients with chronic pulmonary tuberculosis. Tuberc Lung Dis. 2022;100:22–9. Russian. [DOI]

48.

Shanmugasundaram K, Talwar A, Madan K, Bade G. Pulmonary functions and inflammatory biomarkers in post-pulmonary tuberculosis sequelae. Tuberc Respir Dis (Seoul). 2022;85:175–84. [DOI] [PubMed] [PMC]

49.

Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. J Infect Dis. 2005;192:1201–10. [DOI] [PubMed]

50.

Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Physiol Gastrointest Liver Physiol. 2011;301:G950–5. [DOI] [PubMed] [PMC]

51.

Esko JD, Kimata K, Lindahl U. Proteoglycans and sulfated glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, editors. Essentials of glycobiology. 2nd ed. New York (NY): Cold Spring Harbor Laboratory Press; 2009. pp. 229–48. [PubMed]

52.

Karsdal MA, Genovese F, Madsen EA, Manon-Jensen T, Schuppan D. Collagen and tissue turnover as a function of age: implications for fibrosis. J Hepatol. 2016;64:103–9. [DOI] [PubMed]

53.

Kim LB, Shkurupy VA, Putyatina AN. Age-related changes in the system metalloproteinase/tissue metalloproteinase inhibitors and proteoglycan components in mouse organs. Bull Exp Biol Med. 2016;161:32–6. [DOI] [PubMed]

54.

Albeiroti S, Soroosh A, de la Motte CA. Hyaluronan’s role in fibrosis: a pathogenic factor or a passive player? Biomed Res Int. 2015;2015:790203. [DOI] [PubMed] [PMC]

55.

Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M. Extracellular matrix: a matter of life and death. Connect Tissue Res. 2008;49:203–6. [DOI] [PubMed]

56.

Navratilova Z, Zatloukal J, Kriegova E, Kolek V, Petrek M. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease. Respirology. 2012;17:1006–12. [DOI] [PubMed]

57.

Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech. 2014;7:193–203. [DOI] [PubMed] [PMC]

58.

Kaarteenaho-Wiik R, Sademies O, Pääkkö P, Risteli J, Soini Y. Extracellular matrix proteins and myofibroblasts in granulomas of sarcoidosis, atypical mycobacteriosis, and tuberculosis of the lung. Hum Pathol. 2007;38:147–53. [DOI] [PubMed]

59.

da Costa Souza P, Dondo PS, Souza G, Lopes D, Moscardi M, de Miranda Martinho V, et al. Comprehensive analysis of immune, extracellular matrices and pathogens profile in lung granulomatosis of unexplained etiology. Hum Pathol. 2018;75:104–15. [DOI] [PubMed]

60.

Shkurupiy VA. Tuberculous granulomatosis. Cytophysiology and targeted therapy. Moscow: Publishing house of RAMS; 2007. p. 536. Russian.

61.

Kinsella MG, Bressler SL, Wight TN. The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Expr. 2004;14:203–34. [DOI] [PubMed]

62.

Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729–77. [DOI] [PubMed]

63.

Bensadoun ES, Burke AK, Hogg JC, Roberts CR. Proteoglycans in granulomatous lung diseases. Eur Respir J. 1997;10:2731–7. [DOI] [PubMed]

64.

Wight TN, Kang I, Evanko SP, Harten IA, Chang MY, Pearce OMT, et al. Versican—a critical extracellular matrix regulator of immunity and inflammation. Front Immunol. 2020;11:512. [DOI] [PubMed] [PMC]

65.

van Kuppevelt TH, Cremers FP, Domen JG, van Beuningen HM, van den Brule AJ, Kuyper CM. Ultrastructural localization and characterization of proteoglycans in human lung alveoli. Eur J Cell Biol. 1985;36:74–80. [PubMed]

66.

Fleischmajer R, Fisher LW, MacDonald ED, Jacobs L Jr, Perlish JS, Termine JD. Decorin interacts with fibrillar collagen of embryonic and adult human skin. J Struct Biol. 1991;106:82–90. [DOI] [PubMed]

67.

Menozzi FD, Pethe K, Bifani P, Soncin F, Brennan MJ, Locht C. Enhanced bacterial virulence through exploitation of host glycosaminoglycans. Mol Microbiol. 2002;43:1379–86. [DOI] [PubMed]

68.

Petrey AC, de la Motte CA. Hyaluronan, a crucial regulator of inflammation. Front Immunol. 2014;5:101. [DOI] [PubMed] [PMC]

69.

Kamhi E, Joo EJ, Dordick JS, Linhardt RJ. Glycosaminoglycans in infectious disease. Biol Rev Camb Philos Soc. 2013;88:928–43. [DOI] [PubMed]

70.

Gill S, Wight TN, Frevert CW. Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection. Anat Rec (Hoboken). 2010;293:968–81. [DOI] [PubMed] [PMC]

71.

Sampson PM, Boyd RB, Pietra GG, Fishman AP. Glycosaminoglycan biosynthesis in the isolated perfused rat lung. J Appl Physiol Respir Environ Exerc Physiol. 1984;57:1648–54. [DOI] [PubMed]

72.

Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006;20:9–22. [DOI] [PubMed]

73.

Kim LB, Shkurupy VA, Putyatina AN. Dynamic structure of proteoglycans/glycosaminoglycans in the lungs of mice with chronic granulomatous inflammation. Bull Exp Biol Med. 2016;160:435–8. [DOI] [PubMed]

74.

Kim LB, Putiatina AN, Nikonova IK. The serum levels of glycosaminoglycans and hydroxyproline in relation to the age, gender, and blood group of apparently healthy individuals. Klin Lab Diagn. 2011;6:23–5. Russian. [PubMed]

75.

Laurent TC, Fraser JR. Hyaluronan. FASEB J. 1992;6:2397–404. [PubMed]

76.

Hirayama Y, Yoshimura M, Ozeki Y, Sugawara I, Udagawa T, Mizuno S, et al. Mycobacteria exploit host hyaluronan for efficient extracellular replication. PLoS Pathog. 2009;5:e1000643. [DOI] [PubMed] [PMC]

77.

Cherdantseva LA, Potapova OV, Sharkova TV, Anikina AM, Kovner AV, Troitskii AV, et al. Cell death and development of fibrotic alterations in lung granuloma of BALB/c mice during chronic BCG-induced granulomatosis. Bull Exp Biol Med. 2018;165:48–51. [DOI] [PubMed]

78.

Rostand KS, Esko JD. Microbial adherence to and invasion through proteoglycans. Infect Immun. 1997;65:1–8. [DOI] [PubMed] [PMC]

79.

Pasula R, Downing JF, Wright JR, Kachel DL, Davis TE Jr, Martin WJ II. Surfactant protein A (SP-A) mediates attachment of Mycobacterium tuberculosis to murine alveolar macrophages. Am J Respir Cell Mol Biol. 1997;17:209–17. [DOI] [PubMed]

80.

Silva Miranda M, Breiman A, Allain S, Deknuydt F, Altare F. The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria? Clin Dev Immunol. 2012;2012:139127. [DOI] [PubMed] [PMC]

81.

Abraham D, Ponticos M, Nagase H. Connective tissue remodeling: cross-talk between endothelins and matrix metalloproteinases. Curr Vasc Pharmacol. 2005;3:369–79. [DOI] [PubMed]

82.

Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–73. [DOI] [PubMed]

83.

Belton M, Brilha S, Manavaki R, Mauri F, Nijran K, Hong YT, et al. Hypoxia and tissue destruction in pulmonary TB. Thorax. 2016;71:1145–53. [DOI] [PubMed] [PMC]

84.

Tocchi A, Parks WC. Functional interactions between matrix metalloproteinases and glycosaminoglycans. FEBS J. 2013;280:2332–41. [DOI] [PubMed]

85.

Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 2017;147:1–73. [DOI] [PubMed] [PMC]

86.

Laronha H, Caldeira J. Structure and function of human matrix metalloproteinases. Cells. 2020;9:1076. [DOI] [PubMed] [PMC]

87.

Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21:9739. [DOI] [PubMed] [PMC]

88.

Shevchenko OS, Ovcharenko IA, Todoriko LD. Pathophysiological mechanisms destruction of the lung connective tissue in tuberculosis. Infusion Chemother. 2019:14–20. Ukrainian. [DOI]

89.

Lavrova AI, Esmedljaeva DS, Belik V, Postnikov EB. Matrix metalloproteinases as markers of acute inflammation process in the pulmonary tuberculosis. Data. 2019;4:137. [DOI]

90.

Costanzo L, Soto B, Meier R, Geraghty P. The biology and function of tissue inhibitor of metalloproteinase 2 in the lungs. Pulm Med. 2022;2022:3632764. [DOI] [PubMed] [PMC]

91.

Rose KWJ, Taye N, Karoulias SZ, Hubmacher D. Regulation of ADAMTS proteases. Front Mol Biosci. 2021;8:701959. [DOI] [PubMed] [PMC]

92.

Tallant C, Marrero A, Gomis-Rüth FX. Matrix metalloproteinases: fold and function of their catalytic domains. Biochim Biophys Acta. 2010;1803:20–8. [DOI] [PubMed]

93.

Rangasamy L, Geronimo BD, Ortín I, Coderch C, Zapico JM, Ramos A, et al. Molecular imaging probes based on matrix metalloproteinase inhibitors (MMPIs). Molecules. 2019;24:2982. [DOI] [PubMed] [PMC]

94.

Reynolds JJ. Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation. Oral Dis. 1996;2:70–6. [DOI] [PubMed]

95.

Denis M. Neutralization of transforming growth factor-beta 1 in a mouse model of immune-induced lung fibrosis. Immunology. 1994;82:584–90. [PubMed] [PMC]

96.

Marshall BG, Wangoo A, Cook HT, Shaw RJ. Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis. Thorax. 1996;51:1253–61. [DOI] [PubMed] [PMC]

97.

Das V, Bhattacharya S, Chikkaputtaiah C, Hazra S, Pal M. The basics of epithelial-mesenchymal transition (EMT): a study from a structure, dynamics, and functional perspective. J Cell Physiol. 2019;234:14535–55. [DOI] [PubMed]

98.

Saito A, Horie M, Nagase T. TGF-β signaling in lung health and disease. Int J Mol Sci. 2018;19:2460. [DOI] [PubMed] [PMC]

99.

Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol. 2002;21:473–82. [DOI] [PubMed]

100.

Chujo S, Shirasaki F, Kawara S, Inagaki Y, Kinbara T, Inaoki M, et al. Connective tissue growth factor causes persistent proα2(I) collagen gene expression induced by transforming growth factor-β in a mouse fibrosis model. J Cell Physiol. 2005;203:447–56. [DOI] [PubMed]

101.

Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol. 2003;81:355–63. [DOI] [PubMed]

102.

Wang Q, Usinger W, Nichols B, Gray J, Xu L, Seeley TW, et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair. 2011;4:4. [DOI] [PubMed] [PMC]

103.

Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, et al. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-β and IL-10. Eur Respir J. 2003;22:69–76. [DOI] [PubMed]

104.

Barbarin V, Xing Z, Delos M, Lison D, Huaux F. Pulmonary overexpression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles. Am J Physiol Lung Cell Mol Physiol. 2005;288:L841–8. [DOI] [PubMed]

105.

Nakagome K, Dohi M, Okunishi K, Tanaka R, Miyazaki J, Yamamoto K. In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-β in the lung. Thorax. 2006;61:886–94. [DOI] [PubMed] [PMC]

106.

Sziksz E, Pap D, Lippai R, Béres NJ, Fekete A, Szabó AJ, et al. Fibrosis related inflammatory mediators: role of the IL-10 cytokine family. Mediators Inflamm. 2015;2015:764641. [DOI] [PubMed] [PMC]

107.

Kathamuthu GR, Kumar NP, Moideen K, Nair D, Banurekha VV, Sridhar R, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases are potential biomarkers of pulmonary and extra-pulmonary tuberculosis. Front Immunol. 2020;11:419. [DOI] [PubMed] [PMC]

108.

Salgame P. MMPs in tuberculosis: granuloma creators and tissue destroyers. J Clin Invest. 2011;121:1686–8. [DOI] [PubMed] [PMC]

109.

Filonenko TG. Peculiarities of collagen IV localization in fibrous-cavernous tuberculosis. Tavricheskiy Mediko-Biologicheskiy Vestnik. 2012;15:272–6. Russian.

110.

Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002;3:207–14. [DOI] [PubMed]

111.

Rowland SS, Ruckert JL, Burall BN Jr. Identification of an elastolytic protease in stationary phase culture filtrates of M. tuberculosis. FEMS Microbiol Lett. 1997;151:59–64. [DOI] [PubMed]

112.

Ribeiro-Guimarães ML, Pessolani MC. Comparative genomics of mycobacterial proteases. Microb Pathog. 2007;43:173–8. [DOI] [PubMed]

113.

Elkington P, Shiomi T, Breen R, Nuttall RK, Ugarte-Gil CA, Walker NF, et al. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest. 2011;121:1827–33. [DOI] [PubMed] [PMC]

114.

Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z. Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuberc Lung Dis. 2002;6:713–9. [PubMed]

115.

Esmedlyaeva DS, Аlekseeva NP, Gavrilov PV, Pavlova MV, Dyakova ME, Sokolovich EG. The predictive function of rates of matrix metalloproteinases/inhibitors system when assessing reparative changes in the lung tissue in those with infiltrate pulmonary tuberculosis. Tuberc Lung Dis. 2018;96:38–44. Russian. [DOI]

116.

Ugarte-Gil CA, Elkington P, Gilman RH, Coronel J, Tezera LB, Bernabe-Ortiz A, et al. Induced sputum MMP-1, -3 & -8 concentrations during treatment of tuberculosis. PLoS One. 2013;8:e61333. [DOI] [PubMed] [PMC]

117.

Sumenkova DV, Russkikh GS, Poteryaeva ON, Polyakov LM, Panin LE. Activity of matrix metalloproteinases during antimycobacterial therapy in mice with simulated tuberculous inflammation. Bull Exp Biol Med. 2013;155:34–6. [DOI] [PubMed]

118.

Zhang B, Li H, Zhang J, Hang Y, Xu Y. Activating transcription factor 3 protects alveolar epithelial type II cells from Mycobacterium tuberculosis infection-induced inflammation. Tuberculosis (Edinb). 2022;135:102227. [DOI] [PubMed]

119.

Kübler A, Luna B, Larsson C, Ammerman NC, Andrade BB, Orandle M, et al. Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation. J Pathol. 2015;235:431–44. [DOI] [PubMed] [PMC]

120.

Quiding-Järbrink M, Smith DA, Bancroft GJ. Production of matrix metalloproteinases in response to mycobacterial infection. Infect Immun. 2001;69:5661–70. [DOI] [PubMed] [PMC]

121.

Rivera-Marrero CA, Schuyler W, Roser S, Roman J. Induction of MMP-9 mediated gelatinolytic activity in human monocytic cells by cell wall components of Mycobacterium tuberculosis. Microb Pathog. 2000;29:231–44. [DOI] [PubMed]

122.

Kim LB, Putyatina AN, Russkikh GS, Shkurupy VA. Effect of liposome-encapsulated dextrazide on local regulation of extracellular matrix metabolism in liver and lungs of mice with during chronic BCG-induced granulomatosis. Bull Exp Biol Med. 2021;170:640–4. [DOI] [PubMed]

123.

Kim LB, Putyatina AN, Russkikh GS. The role of perlecan in remodeling the extracellular matrix of the liver, lungs and spleen of mice after administration of BCG vaccine and the liposome-encapsulated dextrazide. Exp Clin Gastroenterol. 2022;207:204–10. Russian. [DOI]

124.

Karpov MA, Shkurupy VA, Troitskii AV. The study of efficiency of the approach to prevent the adhesions in the abdominal cavity of rats. Bull Exp Biol Med. 2021;171:416–20. [DOI] [PubMed]

125.

Kim LB, Putyatina AN, Russkikh GS, Komkov NA. Effect of oxidized dextran on the adhesive process in rats. Polytrauma. 2023:83–8. Russian.

126.

Kim LB, Putyatina AN, Russkikh GS, Shkurupy VA. Effect of liposomal delivery of oxidized dextran with isonicotinic acid hydrazide on component profile of pulmonary extracellular matrix in mice with BCG-induced granulomatosis. Bull Exp Biol Med. 2019;168:259–63. [DOI] [PubMed]

127.

Neshchadim DV, Arkhipov SA, Shkurupy VA, Akhramenko ES, Troitsky AV. Study of the influence of luposomes with dekstrazid on the expression of metalloproteinases MMP-1 and MMP-9 by macrophages in vitro. Int J Appl Fundam Res. 2016;8:198–202. Russian.

128.

Kim LB, Putyatina AN, Russkikh GS, Shkurupy VA. Antifibrotics effect of liposome-encapsulated composition of oxidized dextran and isonicotinic acid hydrazide in mice with BCG-induced granulomatosis depends on administration route. Bull Exp Biol Med. 2020;169:71–6. [DOI] [PubMed]

129.

Kozhin PM, Chechushkov AV, Zaytseva NS, Khrapova MV, Cherdantseva LA, Menshchikova EB, et al. Expression of protein genes participating in fibroplastic processes in mice lung during the development of tuberculous inflammation. Siberian Sci Med J. 2019;39:22–9. Russian. [DOI]

130.

Kim LB, Putyatina AN, Russkikh GS, Shkurupy VA. Content of the major extracellular matrix components of the liver and lung in mice with chronic BCG-granulomatosis treated with liposome-encapsulated dextrazide. Bull Exp Biol Med. 2021;170:453–7. [DOI] [PubMed]

131.

Kim LB, Putyatina AN, Russkikh GS, Shkurupy VA. Specific parameters of extracellular matrix remodeling of liver and lungs of mice with BCG granulomatosis during chronic inflammation depending on the method of administration of liposomal oxidized dextran. Tuberc Lung Dis. 2021;99:40–6. Russian. [DOI]